Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PLRZ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.61M
- EPS (TTM)
- -$4.97
- Dividend yield
- None
- 52-week range
- 2.88 – 18.20
- Day range
- 9.26 – 9.90
- Volume / Avg
- 4.85K / 38.21K
- Beta
- —
- Shares outstanding
- 2.43M
52-week range
PLRZ stock today
Shares of Polyrizon (PLRZ) finished lower on Nov 20 at $9.31, a drop of 8.42% or $0.8557 per share, versus the S&P 500's 3.70% decline. Trading was light, with 4.85K shares changing hands, about 13% of the average daily volume. At this level, PLRZ sits in the middle of its 52-week range of $2.88 to $18.20: 48.8% below the high, set on Dec 4, 2025 and 223.3% above the low.
PLRZ is up 9.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 144.0%. Polyrizon has posted a net loss over the last twelve months (EPS of -$4.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Polyrizon
Company profilePolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Tomer Izraeli
- Headquarters
- Ra'anana
- Employees
- 2
- IPO year
- 2024
- Website
- polyrizon-biotech.com
Financial highlights
Full financialsPolyrizon reported a net loss of $3.3 million, compared with a loss of $1.5 million a year earlier. Diluted earnings per share came in at $4.90, down from $805.20.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-3.33M | $-1.54M | $-600.00K | $-779.00K |
| EPS (diluted) | $4.90 | $805.20 | $494.40 | $0.60 |
PLRZ news
All PLRZ newsPolyrizon peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DAVIDavion Healthcare Plc | 0.9001 | -9.99% | $22.50M | vs PLRZ |
| PMIPicard Medical Inc. | 6.79 | +7.78% | $18.07M | vs PLRZ |
| BEATHeartbeam Inc. | 0.2751 | -10.94% | $17.42M | vs PLRZ |
| NEPHNephros Inc. | 2.61 | -8.10% | $28.37M | vs PLRZ |
| RVPRetractable Technologies Inc. | 0.558 | -6.84% | $16.70M | vs PLRZ |
| MODDModular Medical Inc. | 1.68 | -11.81% | $16.36M | vs PLRZ |
| NSPRInspireMD Inc. | 0.54 | -12.97% | $29.23M | vs PLRZ |
| XTNTXtant Medical Holdings Inc. | 0.21 | -2.82% | $29.49M | vs PLRZ |
Indexes, lists and sector
Polyrizon stock FAQ
What is Polyrizon's stock price today?
PLRZ last traded at $9.31 as of Nov 20, 4:00 PM EST, down 8.42% on the day. Prices are delayed at least 15 minutes.
Does Polyrizon pay a dividend?
No. Polyrizon does not currently pay a regular cash dividend.
Who is Polyrizon's CEO?
Mr. Tomer Izraeli is the chief executive officer of Polyrizon Ltd., which has about 2 employees.
Has PLRZ ever split its stock?
Yes. The most recent PLRZ stock split was a 1-for-6 split on Nov 28, 2025, one of 2 splits on record.
What is the PLRZ 52-week high?
The 52-week high for PLRZ is $18.20 and the 52-week low is $2.88. The stock is currently 48.8% below its high.